Skip to main content
. 2016 Nov 1;6(11):2575–2586.

Figure 1.

Figure 1

The levels of miR-101 and USP22 in PTC tissues and cell lines and the association between miR-101 expression and clinicopathological characteristics of PTC. (A) qPCR analysis of miR-101 expression in PTC (T) and the adjacent non-cancerous (N) tissues (n = 20). U6 was used as the endogenous control. (B) Kaplan-Meier survival curves of 60 PTC patients divided by miR-101 levels. (C) The association between miR-101 expression and lymph node metastasis (n = 120). (D) qPCR analyses of USP22 mRNA levels in T and N tissues (n = 20). GAPDH was used as the internal control. (E) The inverse association of miR-101 level and USP22 expression in PTC patients. (F) Western blot analysis of USP22 protein expression in T and N tissues. β-actin was used as the internal control. qPCR (G) and Western blot (H) assays were performed to determine miR-101 and USP22 expression in five PTC cell lines (HTH83, TPC-1, K1, NIM-1 and B-CPAP) and a Nthy-ori 3-1 cell line. U6 and β-actin were used as the endogenous controls. All data are shown as means ± SD of three separate experiments. *P < 0.05, **P < 0.01, as compared with N group (A, D); **P < 0.01, as compared with Nthy-ori 3-1 group (G).